Solid Biosciences Inc./$SLDB

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Solid Biosciences Inc.

Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.

Ticker

$SLDB
Primary listing

Industry

Biotechnology

Employees

100

ISIN

US83422E2046

SLDB Metrics

BasicAdvanced
$373M
-
-$2.92
2.33
-

Bulls say / Bears say

JMP Securities initiated coverage of Solid Biosciences with a 'Market Outperform' recommendation, suggesting a potential upside of over 250% from its current price. (nasdaq.com)
Truist Securities began coverage on Solid Biosciences with a 'Buy' rating, indicating strong confidence in the company's future performance. (nasdaq.com)
The company's inclusion in the Russell 3000® Index reflects its significant progress and potential for increased visibility among investors. (stockhouse.com)
Insider selling activity, including the CEO selling 11,114 shares, may indicate a lack of confidence in the company's short-term prospects. (etfdailynews.com)
The company's projected annual non-GAAP EPS is -2.23, indicating ongoing financial losses that could impact investor sentiment. (nasdaq.com)
Despite positive analyst coverage, the stock's current price remains significantly below the average one-year price target, suggesting potential market skepticism. (nasdaq.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SLDB

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs